Introduction
============

Multiple myeloma (MM) is a malignant plasma cell (PC) disorder and is characterized by the infiltration of malignant PCs, which are the endpoint of B-cell differentiation, in the bone marrow.[@b1-ott-8-1795]--[@b4-ott-8-1795] The mortality of MM is relatively high; approximately 63,000 individuals die from MM annually, accounting for 0.9% of all cancer deaths.[@b5-ott-8-1795] Therefore, many studies have been conducted to explore the molecular mechanisms of MM etiology.[@b6-ott-8-1795],[@b7-ott-8-1795]

MM is known to be associated with heterogeneous cytogenetic abnormalities, including hyperdiploid and nonhyperdiploid karyotypes.[@b8-ott-8-1795] In patients with a nonhyperdiploid karyotype, many chromosomal translocations are involved, which could lead to the altered expression of related proteins (cyclin D1 and cyclin D3) and genes (*WHSC1* and *MAF*).[@b4-ott-8-1795] Additionally, the interaction of genes and proteins are also implicated in the pathogenesis of MM. For instance, a previous study demonstrated that *IL-6* contributes to the pathogenesis of MM and that the concentrations of insulin-like growth factor binding protein-1 and the soluble *IL-6* receptor are positively associated with the risk of MM.[@b9-ott-8-1795]

Despite these significant discoveries, due to the difficulty of obtaining the metaphases of malignant PC clone, there is limited knowledge regarding the genetics of MM due to the difficulty of obtaining malignant PC clones in metaphase. Fortunately, the application of advanced molecular techniques such as microarrays and next-generation sequencing facilitate the improvement of our understanding from a genetic level[@b10-ott-8-1795] Egan et al[@b11-ott-8-1795] and Chapman et al[@b12-ott-8-1795] have analyzed the genomic events that initiate MM using the genomic sequencing.

Microarray data (GSE13591) were established by Agnelli et al[@b13-ott-8-1795] who analyzed these data using a combined FISH and microarray approach and identified near-tetraploidy as a hallmark of the tumor. They also highlighted that loss of heterozygosity is a prominent mechanism in the regulation of mRNA and gene expressions. In their further studies based on these microarray data, the authors provide an elaborate elucidation of the Hedgehog pathway in MM, laying an elaborate foundation for the use of Hedgehog inhibitor detection in clinical trials.[@b14-ott-8-1795] Other investigations based on these microarray data (GSE13591) have also been carried out. Lionetti et al[@b15-ott-8-1795] defined the microRNA/mRNA regulatory network of MM. *HOXB7* expression in MM is identified by both microarray data (GSE13591) analysis and further verification of experiments.[@b16-ott-8-1795],[@b17-ott-8-1795] Moreover, another study reconstructed gene regulatory networks by combining gene expression profiles from seven publicly available datasets; however, the emphasis of this study was to identify critical genes that predict overall survival in the prognosis of MM.[@b18-ott-8-1795]

Nevertheless, none of the aforementioned studies further analyzed the functions, pathways, or the potential correlations of the identified differentially expressed genes (DEGs) between normal and MM PCs. For this study, we downloaded the microarray data (GSE13591) and reanalyzed them using bioinformatics methods including the identification of DEGs in MM, as well as performed the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), protein--protein interaction (PPI), and PPI subnetwork analyses of these DEGs. These approaches are based on multiple bioinformatic packages, which employ powerful statistical methods,[@b19-ott-8-1795],[@b20-ott-8-1795] thus facilitating the identification of critical DEGs and their pathways that are involved in the development of normal PCs into MM. In addition, along with predicting the interactions of the DEGs at the protein level, we aimed to uncover the potential regulatory mechanisms of the relevant genes that contribute to the prognosis and prevention of MM.

Methods
=======

Microarray data and data preprocessing
--------------------------------------

The gene expression profile GSE13591, deposited by Agnelli et al[@b13-ott-8-1795] was downloaded from the Gene Expression Omnibus (GEO) database.[@b21-ott-8-1795] The microarray platform was the GPL96 (HG-U133A) Affymetrix Human Genome U133A Array (Affymetrix, Inc., Santa Clara, CA, USA). The expression profile included 138 samples, comprising five PC samples obtained from normal donors (control group) and 133 PC samples derived from MM patients (MM group).

The raw expression profile data were preprocessed using the Affy package in Bioconductor[@b22-ott-8-1795] and the Affymetrix annotation files from the Brain Array Lab (Microarray Lab, University of Michigan, Ann Arbor, MI, USA). The background correction, quantile data normalization, and probe summarization were performed by the Robust Multi-array Average algorithm to obtain a gene expression matrix.[@b23-ott-8-1795]

Identification of DEGs
----------------------

The DEGs between the MM and control groups were identified based on Student's *t*-test in the linear models for the microarray data (Limma) package.[@b24-ott-8-1795] Raw *P*-values were adjusted into false discovery rates (FDRs) by the Benjamini and Hochberg method.[@b25-ott-8-1795] The thresholds for DEG selection were FDR \<0.05 and \|log~2~FC (fold change)\| \>1.

Functional enrichment analysis of DEGs
--------------------------------------

The GO[@b26-ott-8-1795],[@b27-ott-8-1795] and KEGG[@b28-ott-8-1795] pathway[@b29-ott-8-1795] enrichment analyses were performed to identify the biological functions and pathways of the identified DEGs, based on the hypergeometric distribution algorithm. *P*\<0.05 was chosen as the cut-off value for enriched functions and pathways.

Gene function annotation of DEGs
--------------------------------

By mapping the DEGs using the TRANSFAC database,[@b30-ott-8-1795] the transcription factors among the DEGs were identified. Combined with information from the tumor suppressor gene (TSGene)[@b31-ott-8-1795] and tumor-associated gene (TAG) databases,[@b32-ott-8-1795] all known oncogenes and tumor suppressor genes among the DEGs were extracted.

PPI network construction and module analyses
--------------------------------------------

The DEGs were mapped using the Search Tool for the Retrieval of Interacting Genes (STRING)[@b33-ott-8-1795] database[@b34-ott-8-1795] to reveal potential correlations between the DEGs at the protein level. Only the interaction pairs that contained at least one DEG were selected to construct the PPI network, with the cut-off value of a confidence score \>0.85. Cytoscape software[@b35-ott-8-1795] was used to visualize the PPI network. Furthermore, the PPI subnetwork was identified using BioNet,[@b36-ott-8-1795] and FDR \<0.01 was chosen as the cut-off value. The KEGG pathway enrichment analysis of the genes in the PPI subnetwork was performed.

Results
=======

DEGs between the MM and control groups
--------------------------------------

A total of 166 transcripts, corresponding to 63 DEGs, including 42 downregulated DEGs and 21 upregulated DEGs, were identified between the MM and control groups, as shown in the heat map of the cluster analysis of DEGs ([Figure 1](#f1-ott-8-1795){ref-type="fig"}).

Enrichment analysis of DEGs
---------------------------

GO enrichment analysis revealed that 262 functional terms for downregulated DEGs and 78 for upregulated DEGs were enriched; the top ten functional terms ranked by statistical significance were listed in [Table 1](#t1-ott-8-1795){ref-type="table"} (for down- and upregulated DEGs, respectively). As presented in [Table 1](#t1-ott-8-1795){ref-type="table"}, the top three significantly enriched GO terms for downregulated DEGs were regulation of immune system processes, immune response, and positive regulation of immune system processes (in which *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, and *HMOX1* might be involved; *P*=9.99E-16), whereas the top three for upregulated DEGs were primary metabolic processes (in which *ATF3*, *CCNB1IP1*, *DBF4*, *DUSP5*, and *EEF1E1* may participate; *P*=0.0008866), organic substance metabolic processes (*P*=0.0014942), and response to axon injury (*P*=0.0016905).

The KEGG pathway enrichment analysis revealed that 22 pathways for downregulated DEGs and two pathways for upregulated DEGs were enriched. The top ten significant pathways for downregulated DEGs and the two pathways for upregulated DEGs were shown in [Table 2](#t2-ott-8-1795){ref-type="table"}. Among them, the top three KEGG pathways for downregulated DEGs were intestinal immune network for immunoglobulin (Ig) A production (*P*=5.55E-14), antigen processing and presentation (*P*=7.19E-14), and asthma (*P*=7.84E-14). The enrichment result implied that the genes *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, and *HLA-DRB4* might be involved in the top three pathways. The two enriched pathways for upregulated genes were the mitogen-activated protein kinase signaling pathway (*P*=0.0088912) involving *DUSP5*, *GADD45A*, and *JUND*, and the cell cycle (*P*=0.0178289), involving *DBF4* and *GADD45A*.

Analysis of gene function annotation
------------------------------------

By integrating the information in the TRANSFAC database, there were three transcription factors identified, including one downregulated gene (*CEBPD*) and two upregulated genes (*JUND* and *ATF3*). Additionally, three TAGs, including one downregulated gene (*CEBPD*) and two upregulated genes (*JUND* and *EEF1E1*), were selected.

PPI network and subnetwork analysis
-----------------------------------

The PPI network of genes was constructed, as shown in [Figure 2](#f2-ott-8-1795){ref-type="fig"}. The top ten genes/proteins with the highest degrees (the numbers of PPI pairs that the gene/protein possessed) in the PPI network were *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, *CEBPD*, *HMOX1*, *CD79A*, *TFRC*, *CD19*, and *GADD45A*, with the degrees of 113, 88, 82, 70, 67, 46, 44, 42, 37, and 35, respectively. The PPI subnetwork of genes included 15 nodal genes, of which the top two were *HLA-DRB1* and *VCAM1*, both with a degree of 4, while the degree of *TFRC* was 1 ([Figure 3](#f3-ott-8-1795){ref-type="fig"}).

For the genes identified in the PPI subnetwork, a total of 20 KEGG pathways were enriched ([Table 3](#t3-ott-8-1795){ref-type="table"}). The top three pathways were cell adhesion molecules (*P*=3.86E-06; in which *HLA-DRB1*, *CD4*, *HLA-DMA*, *VCAM1*, and *HLA-DMB* might be involved), the B-cell receptor signaling pathway (*P*=1.13E-05; in which *CD19*, *CD81*, *CD79A*, and *INPP5D* might participate), and antigen processing and presentation (*P*=1.19E-05, in which *HLA-DRB1*, *CD4*, *HLA-DMA*, and *HLA-DMB* might be involved).

Discussion
==========

In this study, a total of 63 DEGs (42 downregulated, 21 upregulated) between the MM and control groups were identified. Based on functional and pathway enrichment analyses by GO and KEGG, genes such as *HLA-DRB1* and *VCAM1* might be involved in the positive regulation of immune system processes; meanwhile, *HLA-DRB1* might also participate in the intestinal immune network for the IgA production pathway. In the PPI network, genes such as *HLA-DRB1* and *TFRC* were ranked in the top ten nodal genes with high degrees. In the PPI subetwork, critical nodal genes, including *HLA-DRB1*, *VCAM1*, *CD4*, and *TFRC*, were identified.

*CD4* encodes a T-lymphocyte membrane glycoprotein, which is a receptor for human immunodeficiency virus and functions to initiate or augment the early phase of T-cell activation.[@b37-ott-8-1795] In patients with MM, although impaired T-cell function and viral-specific cytotoxic T-lymphocytes have been reported, the presence of expanded T-cell populations such as clonal CD4^+^ T-cells has also been detected.[@b38-ott-8-1795] CD4 plays significant roles in immune responses mediated by cells and antibodies.[@b39-ott-8-1795]--[@b41-ott-8-1795] T-helper 17 cells (T~H~17, a new subset of CD4^+^ T-cells) have been suggested as a therapeutic target in MM to improve immune function, as the number of T~H~17 cells is remarkably increased in MM, accompanied by elevated levels of several proinflammatory cytokines.[@b38-ott-8-1795] The antigen specificity of T-cells makes great sense for the immune system.[@b42-ott-8-1795] In the present study, *CD4* was predicted as a crucial nodal gene in the PPI subnetwork and it was implicated in the antigen processing and presentation pathway, indicating that this gene might play a central role in the immune system through the involvement of this pathway in the development of MM cells from normal PCs.

*HLA-DRB1 (major histocompatibility complex, class II, DR Beta 1*), which encodes more than 1,196 alleles, is a polymorphic locus of the HLA system.[@b43-ott-8-1795] It is a member of the HLA class II alpha chain paralogs, which comprise an alpha (DPA) and a beta (DPB) chain and are expressed in antigen-presenting cells.[@b44-ott-8-1795],[@b45-ott-8-1795] Via presenting peptides from extracellular proteins, *HLA-DRB1* plays a pivotal role in the immune system.[@b46-ott-8-1795] For instance, it could bind peptides from antigens and present them on the cell surface to be recognized by CD4 T-cells.[@b47-ott-8-1795] Additionally, *HLA-DPB1* alleles are found to be positively associated with IgA deficiency in German individuals.[@b48-ott-8-1795] Although few studies exist regarding the immune function of *HLA-DPB1* related to MM, our pathway analysis suggests that *HLA-DRB1* might be involved in the intestinal immune network for the IgA production pathway, implying that *HLA-DPB1* might exert a regulatory role in MM development via participation in this pathway. Notably, combined with the potential role of *CD4* and the predicted correlations in the PPI subnetwork, a regulatory relationship between *HLA-DPB1* and *CD4* might exist.

Transferrin receptor (*TFRC*) is closely related to cellular iron intake.[@b49-ott-8-1795] *TFRC* is also related to the immune response.[@b50-ott-8-1795] The blocking of CD4 results in an increasing peptide dose of CD22 and consequently has an intermediate effect on the response of EK35 (one T-cell clone) response to TFRC,[@b51-ott-8-1795] indicating that a relationship might exist between the *CD4* and *TFRC* genes. As revealed in our subnetwork, CD4 was linked to TFRC, and both were predicted to be associated with the hematopoietic cell pathway, providing a clue that *TFRC* might also be involved in MM progression via mediating *CD4*.

*VCAM1* is a member of the Ig superfamily.[@b52-ott-8-1795] *VLA4*, which acts as a cell adhesion receptor of *VCAM1*, mediates the cell adhesion of myeloma cells to bone marrow stroma in MM.[@b53-ott-8-1795] Moreover, the expression of *VLA4* in MM cells could mediate *VCAM1* binding to mesenchymal stem cells.[@b4-ott-8-1795] These results hint that *VCAM1* participates in the pathogenesis of MM through its receptor, *VLA4*. In addition, *VCAM1* was implicated in the cell adhesion molecule pathway in our study. Thus, we speculate that *VCAM1* might contribute to the development of MM via the cell adhesion molecule pathway.

Conclusion
==========

In conclusion, several crucial genes involved in MM were identified, including *CD4*, *HLA-DRB1*, *TFRC*, and *VCAM1*. All of these genes might exert their roles in the progression of normal PCs to MM cells via immune-mediated pathways. Notably, certain regulatory correlations might exist between *HLA-DRB1*, *CD4*, and *TFRC*. However, because the results are based on microarray data with a small sample size, more experimental validations are warranted.
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![The heat map of the cluster analysis of differentially expressed genes.\
**Note:** The X-axis represents samples, while the Y-axis represents genes.](ott-8-1795Fig1){#f1-ott-8-1795}

![Protein--protein interaction network of genes.\
**Note:** The red nodes represent upregulated differentially expressed genes and the green nodes represent downregulated differentially expressed genes, while the yellow nodes represent no differentially expressed genes.](ott-8-1795Fig2){#f2-ott-8-1795}

![Protein--protein interaction in the subnetwork of genes.\
**Notes:** The red nodes represent upregulated differentially expressed genes and the green represent downregulated differentially expressed genes, while the white indicate no differentially expressed genes. The fold change of gene expression is shown in color (deeper color indicates higher fold change of gene expression). The square nodes denote genes with lower importance in the subnetwork, and round nodes denote genes with higher importance.](ott-8-1795Fig3){#f3-ott-8-1795}

###### 

Top ten enriched GO of downregulated DEGs and upregulated DEGs

  DEGs            GO ID        Term                                                   Gene counts   *P*-value   Genes
  --------------- ------------ ------------------------------------------------------ ------------- ----------- --------------------------------------------------------
  Downregulated   GO:0002682   Regulation of immune system process                    21            0           *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, *HMOX1*
                  GO:0006955   Immune response                                        23            0           *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, *HMOX1*
                  GO:0002684   Positive regulation of immune system process           17            9.99E-16    *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, *HMOX1*
                  GO:0050776   Regulation of immune response                          17            8.33E-15    *HLA-DRB1*, *VCAM1*, *A2M*, *CXCL12*, *HMOX1*
                  GO:0002376   Immune system process                                  23            3.26E-14    *HLA-DRB1*, *VCAM1*, *A2M*, *HMOX1*, *CD79A*
                  GO:0002694   Regulation of leukocyte activation                     13            7.57E-14    *HLA-DRB1*, *VCAM1*, *HMOX1*, *CD27*, *HLA-DMA*
                  GO:0045321   Leukocyte activation                                   15            9.87E-14    *HLA-DRB1*, *VCAM1*, *HMOX1*, *CD79A*, *CXCL12*
                  GO:0046649   Lymphocyte activation                                  14            2.09E-13    *HLA-DRB1*, *VCAM1*, *CD79A*, *CXCL12*, *CD27*
                  GO:0050865   Regulation of cell activation                          13            2.10E-13    *HLA-DRB1*, *VCAM1*, *HMOX1*, *CD27*, *HLA-DMA*
                  GO:0051251   Positive regulation of lymphocyte activation           11            3.15E-13    *HLA-DRB1*, *VCAM1*, *CD27*, *HLA-DMA*, *HLA-DPA1*
  Upregulated     GO:0044238   Primary metabolic process                              18            0.0008866   *ATF3*, *CCNB1IP1*, *DBF4*, *DUSP5*, *EEF1E1*
                  GO:0071704   Organic substance metabolic process                    18            0.0014942   *ATF3*, *CCNB1IP1*, *DBF4*, *DUSP5*, *EEF1E1*
                  GO:0048678   Response to axon injury                                2             0.0016905   *TXN*, *UCK2*
                  GO:0008152   Metabolic process                                      18            0.0032882   *ATF3*, *CCNB1IP1*, *DBF4*, *DUSP5*, *EEF1E1*
                  GO:0033554   Cellular response to stress                            6             0.0039691   *ATF3*, *EEF1E1*, *GADD45A*, *MCL1*, *PPP1R15A*, *TXN*
                  GO:0044237   Cellular metabolic process                             17            0.0044393   *ATF3*, *CCNB1IP1*, *DBF4*, *DUSP5*, *EEF1E1*
                  GO:0006259   DNA metabolic process                                  5             0.0045266   *DBF4*, *GADD45A*, *HIST1H1C*, *HIST1H2BK*, *KPNA2*
                  GO:0030968   Endoplasmic reticulum unfolded protein response        2             0.0054425   *ATF3*, *PPP1R15A*
                  GO:0034620   Cellular response to unfolded protein                  2             0.0055648   *ATF3*, *PPP1R15A*
                  GO:0035967   Cellular response to topologically incorrect protein   2             0.0061954   *ATF3*, *PPP1R15A*

**Abbreviations:** GO, Gene Ontology; DEGs, differentially expressed genes; ID, identifier.

###### 

The top ten enriched KEGG pathways of downregulated DEGs and the two enriched KEGG pathways of upregulated DEGs

  DEGs            KEGG pathway                                   Gene counts   *P*-value   Genes
  --------------- ---------------------------------------------- ------------- ----------- ------------------------------------------------------------------------------------------------------------------
  Downregulated   Intestinal immune network for IgA production   9             5.55E-14    *CXCL12*, *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Antigen processing and presentation            10            7.19E-14    *CTSB*, *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA- DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*, *HSPA1A*
                  Asthma                                         8             7.84E-14    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  *Staphylococcus aureus* infection              9             2.08E-13    *C1QA*, *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Allograft rejection                            8             5.09E-13    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Graft-versus-host disease                      8             1.25E-12    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Type 1 diabetes mellitus                       8             1.89E-12    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Autoimmune thyroid disease                     8             9.59E-12    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Rheumatoid arthritis                           9             2.37E-11    *CXCL12*, *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
                  Viral myocarditis                              8             1.15E-10    *HLA-DMA*, *HLA-DPA1*, *HLA-DPB1*, *HLA-DQA1*, *HLA-DQA2*, *HLA-DRB1*, *HLA-DRB3*, *HLA-DRB4*
  Upregulated     MAPK signaling pathway                         3             0.0088912   *DUSP5*, *GADD45A*, *JUND*
                  Cell cycle                                     2             0.0178289   *DBF4*, *GADD45A*

**Abbreviations:** KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes; IgA, immunoglobulin A; MAPK, mitogen-activated protein kinase.

###### 

The 20 enriched KEGG pathways of the protein--protein interaction subnetwork

  KEGG pathway                                   Gene counts   *P*-value     Genes
  ---------------------------------------------- ------------- ------------- --------------------------------------------------
  Cell adhesion molecules                        5             3.86E-06      *HLA-DRB1*, *CD4*, *HLA-DMA*, *VCAM1*, *HLA-DMB*
  B-cell receptor signaling pathway              4             1.13E-05      *CD19*, *CD81*, *CD79A*, *INPP5D*
  Antigen processing and presentation            4             1.19E-05      *HLA-DRB1*, *CD4*, *HLA-DMA*, *HLA-DMB*
  Hematopoietic cell lineage                     4             2.13E-05      *CD19*, *HLA-DRB1*, *CD4*, *TFRC*
  Rheumatoid arthritis                           4             2.43E-05      *HLA-DRB1*, *IL18*, *HLA-DMA*, *HLA-DMB*
  Asthma                                         3             2.57E-05      *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Primary immunodeficiency                       3             4.12E-05      *CD19*, *CD79A*, *CD4*
  Allograft rejection                            3             4.88E-05      *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Graft-versus-host disease                      3             6.66E-05      *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Type 1 diabetes mellitus                       3             7.70E-05      *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Intestinal immune network for IgA production   3             0.000107226   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Malaria                                        3             0.000128658   *CD81*, *IL18*, *VCAM1*
  Autoimmune thyroid disease                     3             0.000136377   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  *Staphylococcus aureus* infection              3             0.000161334   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Phagosome                                      4             0.000186619   *HLA-DRB1*, *HLA-DMA*, *TFRC*, *HLA-DMB*
  Viral myocarditis                              3             0.000330845   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Leishmaniasis                                  3             0.000359628   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  Toxoplasmosis                                  3             0.002107591   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*
  African trypanosomiasis                        2             0.002195842   *IL18*, *VCAM1*
  Systemic lupus erythematosus                   3             0.002295939   *HLA-DRB1*, *HLA-DMA*, *HLA-DMB*

**Abbreviations:** KEGG, Kyoto Encyclopedia of Genes and Genomes; IgA, immunoglobulin A.
